Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$59.18 USD

59.18
1,080,010

-1.25 (-2.07%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $59.17 -0.01 (-0.02%) 6:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day

Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day

Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab

The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.

Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study

Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.

Ekta Bagri headshot

3 Biotech Stocks Worth Adding to Your Portfolio in 2021

We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.

Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans

Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.

REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program

REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy

Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails

Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.

Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1%

Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study

Lexicon (LXRX) initiates dosing in a mid-stage study on LX9211 for the treatment of post-herpetic neuralgia.

Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment

Incyte (INCY) enters into a collaboration with Cellenkos to evaluate the combination of Jakafi and CK0804 in patients with myelofibrosis.

Bristol Myers' (BMY) Application for UC Drug Validated by EMA

Bristol Myers' (BMY) MAA for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis gets validated by EMA.

Exelixis (EXEL) Posts Positive Data From Thyroid Cancer Study

Exelixis' (EXEL) cabozantinib meets the co-primary endpoint in the late-stage study for the treatment of differentiated thyroid cancer following anti-VEGFR therapy.

Roche's (RHHBY) DME Drug Meets Primary Endpoint in Studies

Roche's (RHHBY) investigational bispecific antibody, faricimab, meets the primary endpoints in two late-stage studies for diabetic acular edema.

The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals

The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals

5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic

We take a sneak peek into five healthcare stocks that have performed well in 2020 driven by their improved capabilities to cope with the COVID-19 crisis.

Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235

Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.

Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Lilly (LLY) to Acquire Prevail Therapeutics for Gene Therapies

Lilly (LLY) inks a deal to acquire Prevail Therapeutics for an upfront payment of $880 million, which will add gene therapy programs to its pipeline.

Viatris (VTRS) to Cut Jobs as Part of Restructuring Initiative

Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.

Alexion (ALXN) to Be Acquired by AstraZeneca for $39 Billion

Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.

Gilead (GILD) to Buy MYR GmbH for EUR1.15 Billion in Cash

Gilead (GILD) will purchase MYR GmbH for EUR1.15 billion and add HDV treatment Hepcludex to its portfolio.

Editas (EDIT) Submits Application to Start Study on EDIT-301

Editas (EDIT) files an IND application to the FDA for beginning a phase I/II study of EDIT-301 to treat SCD.

Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND

Exelixis (EXEL) exercises an option to in-license Aurigene's novel CDK7 inhibitor and submits an IND to the FDA for evaluating the candidate in a phase I study.

Gilead's (GILD) Kite Presents Data on CAR T Cell Therapy at ASH

Gilead (GILD) posts positive data on CAR T Cell Therapy Yescarta from multiple studies at ASH.

Regeneron (REGN) Posts Upbeat Data on Myeloma Candidate at ASH

Regeneron (REGN) releases encouraging data from early-stage study on REGN5458 at the ASH 2020.